BRIEF-Vertex says data from study of VX-152 expected in second half of 2017
October 25, 2016 at 16:17 PM EDT
* Announces planned initiation of phase 2 studies evaluating the next-generation correctors VX-440 and VX-152 in triple combination regimens to treat the underlying cause of cystic fibrosis
